Full Title
A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Eugene Pietzak’s office at 646-422-4781.
Protocol
25-383
Phase
Phase II (phase 2)
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT06995677